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Abstract 22 
Objectives: Evidence has shown that a prophylactic antibiotic regimen of flucloxacillin and 23 
gentamicin for orthopaedic surgery was associated with increased rates of post-operative 24 
acute kidney injury (AKI). This resulted in changes in national antibiotic policy 25 
recommendation for orthopaedic surgical prophylaxis. This study aimed to assess whether 26 
this change from flucloxacillin and gentamicin to co-amoxiclav was associated with changes 27 
in the rates AKI and Clostridium difficile infection (CDI).  28 
Methods: An observational study and interrupted time series analyses were used to assess 29 
rates of post-operative AKI separately in patients undergoing neck of femur (NOF) repair and 30 
other orthopaedic operations which required antibiotic prophylaxis. Incidence rate ratios were 31 
used to evaluate changes in CDI rates. 32 
Results: Following the change in policy, from flucloxacillin and gentamicin to co-amoxiclav, 33 
there was a relative change in rates of post-operative AKI of -63% (95% CI -77% to -49%) at 34 
18 months in the other orthopaedic surgeries group. In the NOF repair group, there was no 35 
change in the rate of post-operative AKI -10%, (95% CI -35% to 15%) at 18 months. The 36 
incident rate ratio for CDI in other orthopaedic operations was 0.29 (95%CI 0.09 to 0.96) and 37 
for NOF repair patients was 0.76 (95%CI 0.28 to 2.08). 38 
Conclusions: The use of co-amoxiclav for antibiotic prophylaxis in orthopaedic surgery was 39 
associated with a decreased rate of post-operative AKI compared to flucloxacillin and 40 
gentamicin and was not associated with increased rates of CDI. 41 
42 
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Introduction 43 
Surgical site infections (SSI) are a preventable healthcare associated infection. They are 44 
associated with a significant increase in morbidity, mortality, length of hospital stay and both 45 
socioeconomic and health related costs.1, 2 Prophylactic antibiotics have been shown to 46 
reduce the rate of SSI in patients undergoing joint replacement surgeries3 and are 47 
recommended for orthopaedic implant surgeries.4 However, their use can also have 48 
associated adverse effects and unintended consequences, such as allergy,5 the development of 49 
antibiotic resistance among organisms,6 acute kidney injury (AKI)7-10 and Clostridium 50 
difficile infection (CDI).11, 12 51 
AKI is reported to be an independent risk factor for mortality, as well as being a marker of 52 
co-existing pathologies,13-16 and is a predictor of poor prognosis in hospitalised patients.17-19 53 
AKI is associated with increased risk of the development and progression of chronic kidney 54 
disease (CKD), increased risk of readmission,20 longer hospital stays and higher long term 55 
mortality rates,19 even in patients with transient changes in renal function.20 AKI therefore has 56 
associated important long term socioeconomic and public health effects.  57 
CDI is a healthcare-associated infection with significant associated morbidity and mortality21 58 
that has been under mandatory surveillance in Scotland since 2006,22 and in England since 59 
2004.23 Antibiotic use is associated with an increased risk of CDI for at least 3 months 60 
following administration.24 In order to restrict the use of antibiotics associated with high risk 61 
of CDI25 NHS Tayside orthopaedic antibiotic prophylaxis was changed from cefuroxime to 62 
gentamicin and flucloxacillin in October 2008. Following this, several studies indicated that 63 
prophylaxis with flucloxacillin and gentamicin in orthopaedic patients was associated with a 64 
significant increased rate of post-operative AKI.7-10 Most of these were uncontrolled before 65 
and after studies, but one was a robust quasi-experimental analysis that found the same 66 
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effect.7 In June 2012 within NHS Tayside, policy was changed from flucloxacillin and 67 
gentamicin to co-amoxiclav. 68 
This study aimed to assess whether the change in orthopaedic antibiotic prophylaxis policy 69 
from flucloxacillin and gentamicin to co-amoxiclav was associated with changes in the rates 70 
of post-operative AKI and CDI in adult patients undergoing orthopaedic surgery. The study 71 
also aimed to assess the effect of post-operative AKI on length of hospital stay and one year 72 
post-operative mortality. 73 
Ethical Approval 74 
Anonymised record linkage was conducted according to the Health Informatics Centre (HIC) 75 
standard operating procedure. The Tayside Research Ethics Committee does not require 76 
submission of individual studies that follow this standard operating procedure.  77 
Methods 78 
This study included all adults aged ≥18 years who resided, or died, in the NHS Tayside 79 
region and, who underwent an orthopaedic surgical procedure requiring antibiotic 80 
prophylaxis, between 1st October 2008, and 31st December  2013. Patients were identified by 81 
the Office of Population, Censuses and Surveys Classification of Surgical Operations and 82 
Procedures 4th revision (OPCS-4) codes26 from hospital admissions data (Supplementary 83 
Material, Table 1).  84 
Table 1 shows the recommended antibiotics and doses in NHS Tayside before and after the 85 
2012 policy change. Patients who underwent repair of a neck of femur (NOF) fracture 86 
received co-amoxiclav as antibiotic prophylaxis throughout the period of observation 87 
described here because of concerns raised by orthopaedic surgeons with regard to 88 
administering gentamicin in this particular patient group.  89 
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This study period encompassed 63 months between October 2008 and December 2013. The 90 
study design was an interrupted time series (ITS) with segmented regression analysis27 using 91 
44 monthly time points before and 19 monthly time points after the intervention in June 2012.  92 
Definitions 93 
The definition of postoperative renal impairment used the Kidney Disease Improving Global 94 
Outcomes (KDIGO) criteria.28 (Supplementary Material Table 2) Patients with postoperative 95 
AKI were classified according to their most severe degree of AKI. This was applied using 96 
baseline serum creatinine as the pre-measurement (most recent in the year prior to surgery) 97 
and maximal serum creatinine during the first 7 post-operative days as the post-measurement.  98 
The definition of post-operative CDI was any case with a Clostridium difficile toxin positive 99 
stool sample and/or polymerase chain reaction (PCR) for Clostridium difficile positive result 100 
within 12 weeks post-operatively. Cases were excluded if there had been another positive 101 
sample for Clostridium difficile toxin or PCR in the 12 weeks prior to this, due to the 102 
possibility of this being a recurrence of CDI. 103 
Data Sources 104 
Data were provided by HIC29 at the University of Dundee. Data were linked between the 105 
following datasets: Community Health Index (CHI) register, Scottish Morbidity Record of 106 
hospital admissions (SMR01), OPCS-coded procedures, laboratory results database, 107 
medicines dispensed by community pharmacies, General Register Office death database and 108 
Scottish Care Information – Diabetes Collaboration (SCI-DC). 109 
Age, to the nearest year in the year of surgery, sex and social deprivation, the Scottish Index 110 
of Multiple Deprivation (SIMD) which is linked to residential postal code, were obtained 111 
from the CHI register. A Charlson Comorbidity Index (CCI)30 score was calculated for each 112 
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patient from hospital discharge codes and the number of medication types dispensed from 113 
community pharmacies in the previous three months was applied as an additional measure of 114 
comorbidity.  115 
Exposure to medicines that predispose to renal impairment (NSAIDs, cyclooxygenase-2 116 
inhibitors, angiotensin-converting enzyme inhibitors (ACE I), angiotensin II receptor 117 
antagonists (ARB), diuretics, β-blockers, metformin, other hypoglycaemics and lipid 118 
regulating medications), in the three months prior to the operation was ascertained from 119 
dispensed prescribing data.  120 
Baseline renal function was obtained from the laboratory database. This was the most recent 121 
preoperative serum creatinine measurement in 12 months prior to and including the date of 122 
operation, which could include preoperative samples taken during the current admission. The 123 
median was calculated if there was more than one serum creatinine measurement taken on the 124 
same day. Only patients with both preoperative and postoperative creatinine measurements 125 
could be included. The completeness of creatinine data in each group was measured and 126 
reported (Table 2). Patients already established on renal replacement therapy pre-operatively 127 
were excluded from the analysis. In cases where a patient had a subsequent operation within 128 
7 days of another operation, the second operation was excluded from the analysis. 129 
Statistical Analysis 130 
Monthly rates of AKI were defined by the number of patients with AKI as a proportion of all 131 
patients aged ≥18 years undergoing orthopaedic surgery in each month. Rates were plotted 132 
over time for descriptive purposes and the functional form of the relationship before and after 133 
the intervention was assessed for linearity with splines. Kolmogorov - Smirnov test31 and the 134 
Shapiro – Wilk test32 were used to check data were normally distributed. Segmented 135 
regression analysis of ITS data was used to assess intervention effects on total AKI at 1, 6, 12 136 
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and 18 months after the policy change, with 95% confidence intervals (95%CI)27, 31 and 137 
models were assessed for first order autocorrelation using the Durbin–Watson statistic,33 with 138 
adjustment for autocorrelation using lag terms as required. The effect size at each time point 139 
was converted to a relative percentage difference between the observed and predicted (if the 140 
intervention had not happened) AKI rate. 141 
To assess for the effect of factors other than policy change on total AKI rates multiple linear 142 
regression was used to determine the effects of exposure to medicines that predispose to renal 143 
disease, age, sex and CCI on all rates of AKI in the time periods before and after policy 144 
change.  145 
The monthly rates of CDI were too small to undergo ITS analysis. Due to there being no or 146 
few cases in some months, rates of CDI were calculated using incidence rate ratios34 (IRR) 147 
and 95% CIs. 148 
The median length of stay with IQR was calculated from data extracted from SMR01 data. 149 
Death within 1 year of surgery was calculated as a percentage of all patients who had 150 
undergone operations within each group, in patients with and without post-operative AKI. 151 
All analyses were carried out in IBM SPSS (version 21) and SAS (version 9.2.1) software. A 152 
p-value of <0.05 was considered statistically significant. 153 
The analysis plan included information that addressed the common risks of bias in ITS 154 
studies (Supplementary Material, Table 3). 155 
Results 156 
Data were provided for 14,563 potentially eligible orthopaedic operations in the study period 157 
of October 1, 2008 to December 31, 2013. Of these, five duplicate cases were excluded. 158 
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Cases were split into two groups, Group 1 (n=12707): patients who underwent orthopaedic 159 
operations other than NOF repair, as identified by the International Statistical Classification 160 
of Diseases and Related Health Problems ICD9/10 main condition codes, and Group 2 161 
(n=1851): patients who underwent a NOF repair operation.  Patients were excluded if they 162 
were on the renal replacement register (Group 1 n=33 (0.26%), Group 2 n=8 (0.43%)), if the 163 
operation was within 7 days of a previous operation (Group 1 n=22 (0.17%), Group 2 n=0) or 164 
if creatinine data were missing (Group 1 n=3410 (26.8%), Group 2 n=81 (4.38%)). In total, 165 
11,004 cases were included (Figure 1). 166 
Compared to patients in the other orthopaedic operation group, patients in the NOF group 167 
were older, were more likely to be female and had higher CCI scores (Table 1). However, 168 
baseline creatinine was no worse in NOF patients compared with the other orthopaedic 169 
operation group, median creatinine 69 µmol/L (IQR 53-94) versus 68 µmol/L (IQR 57-80) 170 
respectively. 171 
Table 1 includes the percentage of missing creatinine data within each sub-group. The 172 
majority of missing creatinine measurements were post-operative. There were fewer missing 173 
creatinine data for patients with NOF repair operations. An examination of the characteristics 174 
of patients included versus patients who were excluded due to missing data showed that the 175 
included patients were, on average, older patients with higher CCI comorbidity scores 176 
(Supplementary Material, Table 4).  177 
Acute Kidney Injury 178 
The majority of AKI was mild (Stage 1) AKI (Table 2). Overall, AKI was more common in 179 
the NOF repair patients (Group 2) and affected a slightly higher proportion overall in the 180 
second study period, while Group 1 had a slightly lower proportion of patient with AKI in the 181 
second study period (after prophylaxis changed). 182 
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All other orthopaedic surgeries (Group 1) 183 
The monthly proportion of patients with any stage of post-operative AKI in Group 1 fell 184 
following the intervention (Figure 2A) and interrupted time series analysis indicated a 185 
relative change of -63% (95% CI -77% to -49%) 18 months after the policy change (Table 3).  186 
Multiple linear regression analyses were performed to assess for the effects of sex, age, CCI 187 
and the use of other nephrotoxic drugs. In addition to the policy change only ACE I/ARB 188 
were significantly associated with an increase in rates of post-operative AKI (β=0.186; 95% 189 
CI, 0.03 to 0.342; p=0.02).  190 
Neck of Femur repair (Group 2) 191 
Over the whole period of observation AKI rates in this group were highest, and they had most 192 
variation in the year preceding the change in antibiotic policy for the other group (Figure 2B). 193 
From interrupted time series analysis, there were statistically significant reductions in AKI 194 
rates in the following year but these were much smaller relative changes than in Group 1 and 195 
there was no significant change at 18 months after the policy change -10%, (95% CI -35% to 196 
15%, Table 3).  197 
Multiple linear regression analyses were performed to assess for the effects of sex, age, CCI 198 
and the use of other nephrotoxic drugs. Only ACE I/ARB were significantly associated with 199 
an increase in rates of post-operative AKI (β=0.2520; 95% CI, 0.04 to 0.464; p= 0.02). 200 
Other outcomes 201 
Death within 1 year of surgery 202 
A higher proportion of patients with AKI died within 1 year of surgery compared with 203 
patients without AKI in both the NOF operations group 36.63% (n=89) versus 25.15% 204 
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(n=382), respectively (chi-square=14.09 df=1 p<0.001) and the other orthopaedic operations 205 
group 10.48% (n=108) versus 5.18% (n=425), respectively (chi-square=47.33 df=1 p<0.001). 206 
Length of hospital stay 207 
In the other orthopaedic operations group the median length of hospital stay was 6 days (IQR 208 
11-3) in patients with post-operative AKI compared with 5 days (IQR 9-3) in patients without 209 
post-operative AKI. In the NOF repair operation group was 7 days (IQR 11-4) in patients 210 
with post-operative AKI compared with 6 days (IQR 10-3) in patients without post-operative 211 
AKI. 212 
Clostridium difficile infection and SSI Rates 213 
There was no change in the rate of CDI before and after the policy change in either group. 214 
The CDI IRR (95% CI) for the NOF repair group was 0.76 (0.28 to 2.08) and for other 215 
operations was 0.29 (0.09 to 0.96). 216 
Audits of SSI rates were not done consistently for all types of surgery in the study population 217 
throughout the study period; however the SSI rates among the procedures audited were low 218 
throughout the study period with no apparent change in rate accompanying the policy 219 
changes 220 
Discussion 221 
This large observational study of >14,500 patients, found that a change in prophylactic 222 
antibiotic policy from flucloxacillin and gentamicin to co-amoxiclav was associated with 223 
decreased rates of post-operative AKI in patients undergoing orthopaedic surgeries 224 
(excluding NOF repairs) in the NHS Tayside Region of Scotland, with the majority of 225 
patients developing mild (Stage 1) AKI. The association with the change in antibiotic policy 226 
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is strengthened because there were much smaller reductions in monthly AKI rates among 227 
patients who underwent NOF repair, who received co-amoxiclav throughout the study period, 228 
and the change at 18 months post policy change was not significant in this group. There was 229 
no change in CDI rates associated with the change in antibiotic policy. 230 
We have shown a reduction in all stages of post-operative AKI by -63% (95% CI -77%,-231 
49%) at 18 months post antibiotic policy change statistically significantly associated with that 232 
change in policy. There are likely to be other factors also contributing to the change in rates 233 
of AKI, supported by the (smaller magnitude and not significant at 18 months) reduction in 234 
NOF patients who were not affected by the policy change. Such factors include anaesthetic 235 
practice and post-operative care, such as the Enhanced Recovery Programme, which aims to 236 
optimise pre- and post-operative care including reducing the physical stress of the operation, 237 
promoting effective analgesia and encouraging early mobilisation and oral nutrition. This 238 
programme may lead to an increase in rates of post-operative AKI, as patients may be 239 
exposed to more nephrotoxic analgesics and less fluid replacement in the post-operative 240 
period than before. There has also been ongoing work throughout our institutions, educating 241 
healthcare professionals around recognition, prevention and management of AKI.  242 
The causes of AKI are multifactorial and reported incidence varies dependent on the 243 
definition used, as well variations in population groups and settings35. The incidence of AKI 244 
in acute hospitalised patients is 5-7.5%, with 30-40% of cases occurring in the surgical 245 
perioperative period.36, 37 This is an important contributor to post-operative morbidity and 246 
mortality35 and research suggests that up to 30% of AKI is iatrogenic and/or potentially 247 
preventable.38 The KDIGO AKI guidelines state that major surgery and trauma are exposures 248 
for non-specific AKI, where there is no specific kidney disease causing AKI. 28 Therefore, it 249 
is important that these patients have their serum creatinine and urine output measured 250 
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alongside their clinical status. In line with previous recommendations7 patients receiving 251 
surgical antibiotic prophylaxis are generally undergoing major surgery and, as a minimum, 252 
should have serum creatinine measured both pre-operatively and at least 24 hours post-253 
operatively. 254 
The unadjusted one year post-operative mortality was higher in patients who had undergone 255 
an NOF repair surgery when compared with those having undergone other orthopaedic 256 
surgeries. Within each subgroup crude 1 year post-operative mortality was higher among 257 
those with post-operative AKI than those without. This is consistent with the previous 258 
findings, including this cohort that AKI contributes to higher mortality.16, 19, 36-38 We did not, 259 
however, find any difference in length of hospital stay, when comparing patients with and 260 
without AKI, which may be because the majority of AKI were stage 1and it is possible that 261 
AKI was not detected until after the patient was discharged so did not impact on inpatient 262 
management. The potential implications of reduced rates of AKI include reduced mortality, 263 
readmission to hospital, progression to CKD and the subsequent socio-economic costs, that 264 
have previously been identified in the literature.20 265 
There was no change in CDI rates in either group, suggesting that this is not related to 266 
changes in surgical prophylactic antibiotic policy. Restrictions on the use of therapeutic 267 
antibiotics considered high-risk for CDI, which are used for longer durations, have 268 
contributed, alongside infection control procedures and a change in circulating strains and 269 
virulence of Clostridium difficile,12, 39 to a reduction in rates of CDI.40 270 
Effective restrictions on the use of therapeutic antibiotics associated with high risk for CDI 271 
have also been shown in the orthopaedic surgery population, without a subsequent effect on 272 
rates of deep SSI.41 Rates of CDI across the UK have fallen. By 2013, in Scotland there had 273 
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been reductions in CDI of greater than 79% since 2007/0842 and in 2013/14, England 274 
reported a reduction in CDI of 76% compared with 2007/08.43 275 
Prophylactic antibiotics in orthopaedic implant surgery reduces the risk of SSI.3 In an ageing 276 
population, it is likely that the number of orthopaedic operations is going to increase, 277 
exposing more individuals to prophylactic antibiotics. Any prophylactic antibiotic should aim 278 
to reduce SSI rates, providing cover for commonly implicated pathogens and considering 279 
local resistance patterns, while also minimising the associated risks of AKI, CDI, antibiotic 280 
resistance and allergies. SSI, AKI and CDI are interlinked. The management of SSI is 281 
antibiotic therapy.  SSI in severe cases can lead to sepsis. Both exposure to certain antibiotics 282 
and sepsis have been identified as risk factors for non-specific AKI.28 Further antibiotic 283 
exposure would also put patients at an increased risk of CDI,24 which itself may result in a 284 
patient becoming dehydrated, another susceptibility for non-specific AKI.28 It is therefore 285 
important to ensure that intended and unintended consequences of changes in policy are 286 
balanced. 287 
The strengths of our study are that we used a robust quasi-experimental study design to 288 
evaluate a real-world policy change, addressed risks of bias for ITS studies in our analysis 289 
plan (Supplementary Material, Table 2), defined operations using OPCS-4 operation 290 
procedure codes (Supplementary Material, Table 3), defined NOF cases using ICD9/10 291 
codes, and used the KDIGO definition of AKI. 292 
We addressed the issues common to all non-randomised studies, including potential 293 
ascertainment and selection biases. Data were prospectively entered into electronic databases 294 
and were not subject to manipulation or bias. ITS is the strongest quasi-experimental design 295 
to assess intervention effects in non-randomised setting. It allows for control of trends that 296 
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exist before the intervention being studied, by using multiple time points before and after the 297 
intervention.44, 45 298 
A weakness of our study is that we were unable to adjust for potential effects of 299 
intraoperative events and other medications prescribed during in-patient stay on AKI rates 300 
because these data are not collected electronically. Furthermore, it is possible that the 301 
changes in diagnostic criteria and methods could have masked a true decrease in CDI 302 
incidence over the study period. 303 
Rates of post-operative AKI were not assessed in 4% of the NOF repair surgery group and 304 
27% of the other orthopaedic operations group because of missing pre-operative and post-305 
operative creatinine data. These patients were younger and had less comorbidity when 306 
compared with patients who were included in the study. This could bias the results in either 307 
direction of estimating the rates of AKI. However, there were similar percentages of missing 308 
creatinine data in the pre-intervention and post-intervention groups. 309 
Previous literature showed that a prophylactic antibiotic regimen of flucloxacillin and 310 
gentamicin in orthopaedic patients was associated with a significant increased rate of AKI. 311 
From the previous research carried out by our group it is not clear whether gentamicin or 312 
flucloxacillin or both antibiotics increased the risk of post-operative AKI, or by what 313 
mechanism.7 However, this study has shown that using co-amoxiclav for antibiotic 314 
prophylaxis in orthopaedic surgery is associated with a decreased rate of post-operative AKI 315 
compared to flucloxacillin and gentamicin and is not associated with an increased rate of 316 
CDI. This study also raises the importance of monitoring the intended and unintended 317 
consequences of policy change within healthcare. 318 
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Table 1. Baseline characteristics and missing creatinine data 
Characteristic Operations other than NOF repair  NOF repair operations 
Before 2012 policy change After 2012 policy change Before 2012 policy change  After  2012 policy change  
Recommended antibiotics (dose) Flucloxacillin (1g) x 4 doses + 
one dose Gentamicin (4mg/kg) 
3 doses Co-amoxiclav (1.2g) 3 doses Co-amoxiclav (1.2g) 3 doses Co-amoxiclav (1.2g) 
Patients (n) 6267 2975 1250 512 
Mean Age (yr) (SD) 68.5 (14) 68.9 (13.6) 80 (11.4) 80.6 (10.2) 
Median Baseline SCr (µmol/L) (IQR) 74 (62-88) 68 (57-80) 72 (57-94) 69 (53-94) 
Sex n(%)  
Female 3619 (57.7) 1774 (59.6) 914 (73.1) 372 (72.7) 
Male 2648 (42.3) 1201 (40.4) 336 (26.9) 140 (27.3) 
SIMD n(%)  
1-3 (most deprived) 1212 (19.3) 573 (19.3) 244 (19.5) 113 (22.1) 
4-7 2679 (42.7) 1299 (43.7) 545 (43.6) 217 (42.4) 
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8-10 (least deprived) 2269 (36.2) 1044 (35.1) 444 (35.5) 171 (33.4) 
CCI n(%)  
Low (0) 5282 (84.3) 2317 (77.9) 789 (63.1) 303  (59.2) 
Medium (1 or 2) 870 (13.9) 584 (19.6) 400 (32) 183 (35.7) 
High (≥3) 115 (1.8) 74 (2.5) 61 (4.9) 26 (5.1) 
Patients before missing creatinine 
exclusions n(%)* 
8515 4137 1304 539 
Missing pre-operative 
creatinine 
453 (5.32) 192 (4.64) 7 (0.54) 4 (0.74) 
Missing post-operative 
creatinine 
1995 (23.43) 1039 (25.11) 49 (3.76) 22 (4.08) 
Missing both pre and post-
operative creatinine 
405 (4.76) 173 (4.18) 4 (0.31) 2 (0.37) 
* Data are presented as n (%) of all patients after exclusion of duplicates, patients on RRT and subsequent operation within 7 days
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Table 2. AKI rates by each stage 
 Operations other than NOF repair  NOF repair operations 
AKI Stage n(%) Before 2012 policy 
change 
After 2012 policy 
change 
Before 2012 
policy change 
After 2012 policy 
change 
1 618 (9.86) 239 (8.03) 153 (12.24) 67 (13.09) 
2 95 (1.52) 22 (0.74) 16 (1.28) 4 (0.78) 
3 45 (0.72) 12 (0.4) 2 (0.16) 1 (0.2) 
None 5509 (87.9) 2702 (90.8) 1079 (86.32) 440 (85.94) 
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Table 3. ITS analyses intervention effects at 1, 6, 12 and 18 months post-policy change for other orthopaedic 
operations and NOF repair operations, all AKI Stages (Rate per 100 patients) 
 Operations other than NOF repair  NOF repair operations 
1 month 6 months 12 months 18 months 1 month 6 months 12 months 18 months 
Absolute 
difference 
-6.1 -8.2 -10.6 -13.1 -4.7 -3.8 -2.8 -1.8 
95% CI (-9.7,-2.6) (-11.2,-
5.2) 
(-13.9,-7.4) (-17.3,-8.9) (-8.8,-0.5) (-7.3,-0.4) (-6.5,0.8) (-6.6,3.0) 
Relative 
change 
-36.0% -45.2% -54.8% -63.2% -28.7% -22.8% -16.1% -10.0% 
95% CI (-54.6%,-
17.4%) 
(-57.7%,-
32.6%) 
(-65.3%,-
44.3%) 
(-77.3%,-
49.1%) 
 (-52.2%, -
5.3%)  
(-40.8%, -
4.8%) 
(-34.6%, 
2.3%) 
(-34.7%, 
14.8%) 
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Figure 1: Summary of case groupings and exclusions 
 
 
 
 
 
 
Figure 2A: AKI (Stages 1-3 combined) in orthopaedic operations other than NOF repair from October 2008 to 
December 2013. The Policy Change was from flucloxacillin plus gentamicin to co-amoxiclav for antibiotic 
prophylaxis. 
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Figure 2B: AKI (Stages1-3 combined) in NOF repair operations from October 2008 to December 2013 with co-
amoxiclav the recommended antibiotic prophylaxis throughout. The Policy Change was for operations other than 
NOF repair. 
 
 
